Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.45 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329073 | 0.92 | RET (0.44) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6337433 | 0.90 | RET (0.43) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6778312 | 0.88 | RET (0.45) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6330789 | 0.88 | RET (0.47) | RETTLK2BRD4AKT2GSK3B | |
| SCHEMBL6333166 | 0.88 | RET (0.44) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6337189 | 0.88 | RET (0.44) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6331394 | 0.87 | RET (0.59) | RETTLK2FLT3FLT4KDR | |
| SCHEMBL6338435 | 0.87 | RET (0.48) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6338814 | 0.87 | RET (0.43) | RETTLK2BRD4GSK3BFLT3 | |
| SCHEMBL6329204 | 0.87 | RET (0.50) | RETTLK2BRD4GSK3BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1212318-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | RET 154/4885TLK2 1364/4885BRD4 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.